Date of Report (date of earliest event reported): November 12, 2015



vTv Therapeutics Inc.

(Exact name of registrant as specified in its charter)





Delaware   001-37524   47-3916571

(State or other jurisdiction

of incorporation)



File No.)


(IRS Employer

Identification No.)

4170 Mendenhall Oaks Pkwy

High Point, NC 27265

(Address of principal executive offices)

(336) 841-0300

(Registrant’s telephone number, including area code)


(Former name or former address, if changed since last report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




Item 2.02 Results of Operations and Financial Condition

On November 12, 2015, vTv Therapeutics Inc. (the “Company”) issued a press release to announce its financial results for the quarter ended September 30, 2015. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.

The information in this report (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended (the “Securities Act”) or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits


Exhibit No.



99.1    Press Release dated November 12, 2015, announcing financial results for the fiscal quarter ended September 30, 2015


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.



/s/ Rudy C. Howard

Name:   Rudy C. Howard
Title:   Executive Vice President and Chief Financial Officer

Dated: November 12, 2015







99.1    Press Release dated November 12, 2015, announcing financial results for the fiscal quarter ended September 30, 2015

Exhibit 99.1

vTv Therapeutics Reports Financial Results for the Third Quarter

Ended September 30, 2015

HIGH POINT, NC – November 12, 2015 – vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease (AD) and diabetes, today reported financial results for the third quarter of 2015 and provided an update on recent developments.

“I’m pleased to report that vTv has had a highly productive quarter and 2015. We advanced our pivotal Phase 3 program for our lead product candidate azeliragon, which has demonstrated positive effects treating mild Alzheimer’s disease, and continue to enroll patients in our STEADFAST Study,” said President and CEO Steve Holcombe. “Coming up in 2016, we expect significant data readouts for our two ongoing diabetes programs. Both of these investigational drugs, including our first-in-class liver selective Glucokinase Activator (GKA) that targets the underlying cause of diabetes and our oral GLP-1r, are contenders for best-in-class oral small molecule treatments in a disease with enormous unmet therapeutic needs.”


Development Programs:

STEADFAST Study in Alzheimer’s Disease


    vTv continues to enroll its Phase 3 study with lead product candidate azeliragon. The randomized, double-blind, placebo-controlled study is evaluating whether the oral, small molecule antagonist of the Receptor for Advanced Glycation Endproducts (RAGE) can slow the cognitive and functional decline of patients with mild Alzheimer’s disease. Successful Phase 2b results of 5mg/day over 18 months showed statistically significant efficacy in mild-to-moderate Alzheimer’s patients (+3.1 points on ADAS-Cog standard measure of cognition) and even greater efficacy in mild patients (+4.0). Benefits were shown on CDR-SB and all secondary endpoints, including a significant reduction of psychiatric events (e.g. anxiety).


    Study has received a Special Protocol Assessment (SPA), and azeliragon continues to be developed under Fast Track designation from the U.S. FDA.


    80 of the targeted 100 clinical sites have been initiated in the United States and Canada.

Page 2


TTP399 AGATA Study in Type 2 Diabetes


    The Company is enrolling patients into a Phase 2b study of its liver-selective Glucokinase Activator, a novel oral, small molecule product candidate with first-in-class potential. The randomized, double-blind, placebo- and active-controlled parallel group trial is evaluating the safety and efficacy of TTP399 following six months administration of 180 Type 2 diabetic patients on a stable dose of metformin.


    Previous Phase 2 clinical data showed that treatment significantly lowered blood glucose in patients in just six weeks, with no hypoglycemia or increase in lipids and no induction of insulin secretion. Within the high dose arm, patients moved from out-of-control diabetes to glucose measures that are considered pre-diabetic.


    On track for mid-2016 data readout of Phase 2b results.

TTP273 LOGRA Study in Type 2 Diabetes


    Clinical team preparing for first quarter 2016 launch of Phase 2b study of its oral, small molecule GLP-1r agonist with best-in-class potential. The randomized, double-blind, placebo-controlled, parallel group trial is evaluating the safety and efficacy of TTP273 in 156 Type 2 diabetics on stable doses of metformin.


    Expect to report Phase 2b data by the end of 2016.


Third Quarter and Nine Months Ended September 30, 2015


    Cash Position: Cash and cash equivalents as of September 30, 2015 were $97.0 million. As of December 31, 2014 the Company had cash and cash equivalents of $1.4 million. The increased cash balance reflects net proceeds of approximately $104.4 million received from the Company’s IPO.


    Research and Development: Expenses were $7.2 million and $20.6 million, respectively, for the three and nine months ended September 30, 2015, compared to $4.3 million and $13.3 million during the comparable periods in 2014. The increases over prior periods were related to increased activity in our clinical trials during the current year.



General and Administrative: Expenses were $2.4 million and $6.7 million, respectively, for the three and nine months ended September 30, 2015, compared to $1.6 million and $9.6 million during the comparable periods in

Page 3


  2014. G&A expenses were up for the three month period due to increased legal and professional fees coupled with an increase in stock based compensation. G&A costs were down for the nine month period ended September 30, 2015 due to higher compensation costs in 2014 related to the departure of a former officer and director.


    Net Loss: The Company reported net loss of $9.8 million for the third quarter of 2015 and $30.0 million for the nine months ended September 30, 2015, compared to a net loss of $5.9 million and $28.4 million for the comparable periods in 2014.

About vTv Therapeutics Inc.

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and Type 2 diabetes as well as treatment of inflammatory disorders and the prevention of muscle weakness.

Forward-Looking Statements

This release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case, their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading “Risk Factors” in our Registration Statement on Form S-1 and our other filings with the SEC. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of

Page 4


new information, future events or otherwise after the date of this release. We anticipate that subsequent events and developments will cause our views to change. Our forward-looking statements do not reflect the potential impact of any future acquisitions, merger, dispositions, joint ventures or investments we may undertake. We qualify all of our forward-looking statements by these cautionary statements.


The Trout Group

Josh Barer, 646-378-2948




BMC Communications

Brad Miles, 646-513-3125


vTv Therapeutics, Inc.

Condensed Consolidated Balance Sheets - Unaudited

(in thousands except per share data)


     September 30,
    December 31,



Current assets:


Cash and cash equivalents

   $ 97,010      $ 1,384   

Restricted cash and cash equivalents

     —          130   

Prepaid expenses and other current assets

     799        97   







Total current assets

     97,809        1,611   

Note receivable

     —          6,594   

Property and equipment, net

     669        3,778   

Receivable due from a related party, net

     —          800   

Employee loans receivable - related party

     48        58   

Other long-term assets

     1,669        110   







Total assets

   $ 100,195      $ 12,951   







Liabilities Redeemable Convertible Preferred Units, Redeemable Noncontrolling Interest, Stockholders’ and Members’ Deficit


Current liabilities:


Accounts payable and accrued expenses

   $ 5,240      $ 3,079   

Accounts payable and accrued expenses - related party

     516        1,752   

Deferred revenue

     320        —     

Short-term debt

     —          155   

Other liabilities

     —          1,878   







Total current liabilities

     6,076        6,864   

Debt - related party

     —          27,310   

Debt, net of current portion

     —          2,110   

Fair value of contingent distribution

     —          26,359   

Note payable

     —          6,594   

Other liabilities, net of current portion

     53        4,434   







Total liabilities

     6,129        73,671   

Commitments and contingencies


Redeemable convertible preferred units

     —          438,086   

Redeemable noncontrolling interest

     188,251        —     

Stockholders’/members’ deficit:


Members’ deficit

     —          (498,806

Class A Common stock, $0.01 par value; 100,000,000 shares authorized, 9,156,686 outstanding as of September 30, 2015

     92        —     

Class B Common stock, $0.01 par value; 100,000,000 shares authorized, 23,655,814 outstanding as of September 30, 2015

     237        —     

Additional paid-in capital

     117,131        —     

Accumulated deficit

     (211,645     —     







Total stockholders’ deficit attributable to vTv Therapeutics Inc./members’ deficit

     (94,185     (498,806







Total liabilities, redeemable convertible preferred units, redeemable noncontrolling interest, stockholders’ and members’ deficit

   $ 100,195      $ 12,951   







vTv Therapeutics, Inc.

Condensed Consolidated Statements of Operations - Unaudited

(in thousands, except per share data)


     Three months ended
September 30,
    Nine months ended
September 30,
     2015     2014     2015     2014  


   $ 133      $ 400      $ 293      $ 615   

Operating expenses:


Research and development

     7,159        4,328        20,638        13,267   

General and administrative

     2,415        1,592        6,707        9,577   













Total operating expenses

     9,574        5,920        27,345        22,844   













Operating loss

     (9,441     (5,520     (27,052     (22,229

Other expense, net

     (381     (350     (2,996     (6,157













Net loss before income taxes

     (9,822     (5,870     (30,048     (28,386

Income tax provision

     —          —          —          —     













Net loss before noncontrolling interest

     (9,822     (5,870     (30,048     (28,386

Less: net loss attributable to noncontrolling interest

     (5,719     —          (5,719     —     













Net loss attributable to vTv Therapeutics Inc.

   $ (4,103   $ (5,870   $ (24,329   $ (28,386













Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic and diluted

   $ (0.49     $ (3.05  







Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, basic and diluted

     8,305,368          7,976,183